| Literature DB >> 35498480 |
Zhao-Kun Yin1, Zi-Ming Feng1, Jian-Shuang Jiang1, Xu Zhang1, Pei-Cheng Zhang1, Ya-Nan Yang1.
Abstract
One new tanshinone derivative, which possesses an unusual 6/6/5/6 fused-ring skeleton system (1), together with four new five-membered lactone benzohexa-membered ring compounds (2, 3, 4A and 4B), and three new carboxyl substituted 5,5-spiroketal compounds (5-7), were isolated from the dried rhizomes of Salvia miltiorrhiza. The structures of these compounds were determined by multiple spectral analyses (UV, IR, NMR, and HR-ESI-MS). In addition, the absolute configurations were established by X-ray diffraction experiments, calculated and experimental circular dichroism spectra. Evaluation of antitumor activity showed that 1 had strong cytotoxicity to tumor-repopulating cells (TRCs) with an IC50 value of 2.83 μM. In the evaluation of neuroprotective activity, 4A and 6 showed a strong improvement in the survival rates of SK-N-SH cell injury induced by oxygen glucose deprivation (OGD). This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35498480 PMCID: PMC9051908 DOI: 10.1039/d0ra02022b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1The structures of compounds 1–7.
1H NMR (500 MHz) and 13C NMR (125 MHz) data of compounds 1–4
| No. | 1 | 2 | 3 | 4A/4B | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| 1 | 8.32, d (8.5) | 123.2 | 5.19, dd (5.5, 12.0) | 78.0 | 5.19, dd (5.5, 12.0) | 77.8 | 5.22, dd (5.5, 11.5) | 77.8 |
| 2 | 7.65, dd (6.5, 8.5) | 127.8 | 2.39, m, 1.62, m, 1.62, m | 26.3 | 2.39, m, 1.62, m | 26.3 | 2.40, m, 1.62, m | 26.3 |
| 3 | 7.61, d (6.5) | 130.5 | 1.92, m, 1.85, m | 38.0 | 1.92, m, 1.85, m | 38.2 | 1.92, m, 1.86, m | 37.1 |
| 4 | 133.5 | 34.9 | 34.9 | 34.9 | ||||
| 5 | 135.9 | 144.6 | 144.8 | 144.1 | ||||
| 6 | 8.30, d (8.5) | 128.4 | 7.55, d (8.0) | 131.1 | 7.55, d (8.0) | 131.5 | 7.65, d (8.0) | 131.2 |
| 7 | 7.79, d (8.5) | 118.3 | 7.47, d (8.0) | 130.0 | 7.47, d (8.0) | 130.0 | 7.52, d (8.0) | 130.3 |
| 8 | 129.2 | 126.9 | 126.8 | 126.5 | ||||
| 9 | 148.9 | 122.9 | 123.2 | 123.0 | ||||
| 10 | 136.4 | 148.0 | 148.0 | 148.3 | ||||
| 11 | 78.9 | 168.5 | 168.5 | 168.9 | ||||
| 12 | 83.4 | 170.1 | 170.1 | 169.0 | ||||
| 13 | 202.0 | 111.5 | 111.6 | 122.5 | ||||
| 14 | 173.0 | 163.3 | 163.0 | 154.0 | ||||
| 15 | 3.95, dd (3.5, 12.0), 3.15, t (12.0) | 68.2 | 4.72, t, (9.0), 4.23, dd (5.5, 9.0) | 78.9 | 4.70, t (9.0), 4.24, dd (5.5, 9.0) | 78.9 | 7.32, s | 140.6 |
| 16 | 2.28, m | 40.5 | 3.49, m | 37.2 | 3.40, m | 37.1 | 117.0 | |
| 17 | 0.93, d (7.5) | 11.3 | 1.34, d (6.5) | 19.6 | 1.38, d, (7.0) | 20.0 | 2.23, s | 10.1 |
| 18 | 2.72, s | 19.6 | 1.44, s | 31.8 | 1.44, s | 31.8 | 1.45, s | 31.8 |
| 19 | 1.19, s | 30.9 | 1.19, s | 31.0 | 1.22, s | 31.0 | ||
| OH-11 | 6.70, s | |||||||
| OH-12 | 6.34, s | |||||||
Data were measured in DMSO-d6.
Data were measured in CDCl3.
Fig. 2Key HMBC correlations of compounds 1, 2, 5.
Fig. 3The ROESY correlations of compounds 1, 5–7.
Fig. 4Experimental and calculated ECD spectra of 1.
Fig. 5ORTEP diagram of 2.
1H NMR (500 MHz) and 13C NMR (125 MHz) data of compounds 5–7 in CDCl3
| No. | 5 | 6 | 7 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 8.78, d (8.5) | 122.5 | 8.82, d (8.5) | 122.4 | 3.17, t (6.0) | 26.1 |
| 2 | 7.56, dd (7.0, 8.5) | 129.1 | 7.57, t (7.0, 8.5) | 129.1 | 1.82, m | 18.6 |
| 3 | 7.44, d (7.0) | 128.7 | 7.45, d (7.0) | 128.7 | 1.68, m | 38.4 |
| 4 | 129.3 | 129.3 | 34.6 | |||
| 5 | 133.7 | 133.7 | 149.2 | |||
| 6 | 8.33, d (8.5) | 132.3 | 8.32, d (8.5) | 132.1 | 7.62, d (8.0) | 133.2 |
| 7 | 7.55, d (8.5) | 118.0 | 7.48, d (8.5) | 117.7 | 7.18, d (8.0) | 118.9 |
| 8 | 146.2 | 146.4 | 144.4 | |||
| 9 | 122.2 | 122.9 | 124.5 | |||
| 10 | 135.3 | 135.2 | 137.9 | |||
| 11 | 168.2 | 168.5 | 169.0 | |||
| 12 | 111.4 | 109.8 | 109.8 | |||
| 13 | 4.51, t (8.0), 3.85, t (8.0) | 76.1 | 4.45, t (8.0), 4.07, dd (3.5, 8.5) | 76.6 | 4.36 t (7.5), 3.97, dd (3.5, 8.5) | 76.2 |
| 14 | 3.22, m | 34.6 | 3.04, m | 34.4 | 2.94, m | 34.3 |
| 15 | 3.20, overlap | 59.2 | 3.63, d (8.0) | 54.7 | 3.48, d (8.0) | 55.4 |
| 16 | 1.32, d (5.5) | 17.1 | 1.43, d (7.0) | 16.3 | 1.28, s | 16.1 |
| 17 | 172.2 | 171.6 | 172.3 | |||
| 18 | 2.71, s | 20.0 | 2.72, s | 20.0 | 1.30, s | 32.0 |
| 19 | 1.30, s | 31.9 | ||||
Scheme 1Plausible biogenetic pathway for 1.
Scheme 2Plausible biogenetic pathway for 2/3 and 7.